IPCA Laboratories Stock Screener | Share Price & Fundamental Analysis
IPCALAB
Pharmaceuticals
Screen IPCA Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1413.00
▲
9.00 (0.64%)
Share Price BSE
₹1414.00
▲
10.25 (0.73%)
Market Cap
₹35,472.92 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
4.86
EPS (TTM)
₹29.08
Dividend Yield
0.28%
Debt to Equity
0.21
52W High
₹1693.85
52W Low
₹1268.70
Operating Margin
10.00%
Profit Margin
2.82%
Revenue (TTM)
₹2,273.00
EBITDA
₹250.00
Net Income
₹64.00
Total Assets
₹11,761.00
Total Equity
₹8,388.00
IPCA Laboratories Share Price History - Stock Screener Chart
Screen IPCALAB historical share price movements with interactive charts. Analyze price trends and patterns.
IPCA Laboratories Company Profile - Fundamental Screener
Screen IPCA Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for IPCALAB shares.
Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts. The company's facilities are approved by major drug regulatory authorities including the US FDA, UK MHRA, and others. Ipca has expanded through acquisitions and joint ventures, and has subsidiaries in various countries. The company focuses on research and development, and has recently acquired stakes in other pharmaceutical companies to strengthen its market position.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Premchand Godha
ISIN
INE571A01038
Website
https://www.ipca.com
IPCA Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen IPCALAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 11,761 | 11,101 | 8,626 | 7,624 | 6,068 | 5,260 | 4,551 | 4,117 | 3,960 | 3,892 |
| Current Assets | 5,967 | 5,539 | 5,189 | 4,447 | 3,437 | 2,856 | 2,378 | 1,946 | 1,742 | 1,622 |
| Fixed Assets | 4,267 | 4,553 | 2,751 | 2,402 | 2,072 | 2,059 | 1,940 | 1,953 | 1,983 | 2,014 |
| Liabilities | ||||||||||
| Total Liabilities | 11,761 | 11,101 | 8,626 | 7,624 | 6,068 | 5,260 | 4,551 | 4,117 | 3,960 | 3,892 |
| Current Liabilities | 986 | 1,019 | 905 | 616 | 192 | 292 | 315 | 421 | 548 | 663 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 8,388 | 7,727 | 5,915 | 5,542 | 4,716 | 3,641 | 3,138 | 2,689 | 2,455 | 2,259 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves & Surplus | 6,923 | 6,307 | 5,817 | 5,440 | 4,676 | 3,590 | 3,097 | 2,663 | 2,430 | 2,234 |
Screen IPCALAB income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,273 | 2,342 | 2,584 | 2,052 | 2,113 | 2,381 | 2,266 | 1,548 | 1,630 | 2,073 | 2,144 | 1,304 | 1,608 | 1,637 | 1,577 |
| Expenses | 2,023 | 1,892 | 2,070 | 1,848 | 1,700 | 1,913 | 1,782 | 1,331 | 1,278 | 1,713 | 1,722 | 1,070 | 1,317 | 1,341 | 1,330 |
| EBITDA | 250 | 449 | 515 | 204 | 413 | 468 | 483 | 217 | 353 | 360 | 422 | 234 | 291 | 296 | 247 |
| Operating Profit % | 10.00% | 18.00% | 19.00% | 9.00% | 19.00% | 19.00% | 21.00% | 12.00% | 19.00% | 16.00% | 16.00% | 17.00% | 17.00% | 16.00% | 14.00% |
| Depreciation | 100 | 100 | 103 | 98 | 99 | 100 | 99 | 70 | 69 | 90 | 100 | 61 | 62 | 64 | 67 |
| Interest | 22 | 19 | 20 | 29 | 24 | 23 | 17 | 19 | 31 | 44 | 33 | 3 | 7 | 9 | 11 |
| Profit Before Tax | 128 | 331 | 392 | 77 | 290 | 345 | 368 | 129 | 252 | 225 | 289 | 170 | 223 | 223 | 169 |
| Tax | 64 | 98 | 111 | 75 | 91 | 99 | 92 | 51 | 88 | 89 | 68 | 38 | 78 | 77 | 60 |
| Net Profit | 64 | 233 | 281 | 1 | 199 | 246 | 276 | 78 | 164 | 137 | 221 | 132 | 145 | 146 | 110 |
| EPS | 2.67 | 9.19 | 11.14 | 2.35 | 7.58 | 9.05 | 9.78 | 3.02 | 6.42 | 5.72 | 7.09 | 5.13 | 5.64 | 5.67 | 4.25 |
IPCA Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen IPCALAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,321 | 945 | 806 | 856 | 1,090 | 570 | 501 | 341 | 282 | 709 |
| Investing Activities | -870 | -1,215 | -725 | -851 | -521 | -509 | -165 | -135 | -149 | -218 |
| Financing Activities | -283 | -553 | 507 | 427 | -306 | -137 | -183 | -130 | -159 | -462 |
| Net Cash Flow | 169 | -823 | 588 | 432 | 264 | -76 | 153 | 75 | -26 | 29 |
Screen IPCALAB shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 44.72% | 44.72% | 44.72% | 46.30% | 46.30% | 46.30% | 44.72% | 46.29% |
| FII Holding | 10.76% | 10.67% | 10.43% | 10.51% | 10.85% | 10.83% | 11.07% | 0.02% |
| DII Holding | 36.06% | 36.20% | 36.77% | 34.37% | 33.78% | 34.23% | 35.68% | 33.55% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.81% | 6.82% | 6.55% | 7.13% | 7.27% | 6.93% | 6.88% | 7.26% |
| Other Holding | 1.65% | 1.59% | 1.53% | 1.69% | 1.79% | 1.71% | 1.65% | 12.89% |
| Shareholder Count | 88,306 | 85,582 | 82,870 | 81,165 | 84,753 | 82,975 | 90,189 | 110,296 |
IPCA Laboratories Dividend Screener - Share Yield Analysis
Screen IPCALAB dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹4.00 | 0.28% |
| 2024-March | ₹4.00 | 0.27% |
| 2023-March | ₹4.00 | 0.32% |
| 2022-March | ₹4.00 | 0.51% |
| 2021-March | ₹8.00 | 0.75% |
| 2020-March | ₹5.00 | 0.53% |
| 2019-March | ₹3.00 | 0.43% |
| 2018-March | ₹1.00 | 0.20% |
| 2017-March | ₹1.00 | 0.31% |
IPCA Laboratories Index Membership - Market Screener Classification
Screen IPCALAB by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
IPCA Laboratories Market Events Screener - Corporate Actions
Screen IPCALAB market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 4.12% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | -4.14% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -5.30% |
| 2025-08-05 | 2025-08-05 | Dividend | ₹ 2.00 /share | -3.58% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 6.52% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -6.28% |
| 2024-11-27 | 2024-11-27 | Dividend | ₹ 2.00 /share | 3.99% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -3.83% |
| 2024-08-13 | 2024-08-13 | Annual General Meeting | NA | 13.43% |
| 2024-08-06 | 2024-08-07 | Dividend | ₹ 2.00 /share | 0.12% |
| 2023-11-22 | 2023-11-22 | Dividend | ₹ 2.00 /share | 2.72% |
| 2022-11-22 | 2022-11-23 | Dividend | ₹ 4.00 /share | -2.89% |
| 2021-11-22 | 2021-11-23 | Dividend | ₹ 8.00 /share | -8.50% |
IPCA Laboratories Competitors Screener - Peer Comparison
Screen IPCALAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
IPCA Laboratories Company Announcements - News Screener
Screen IPCALAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-28 | Closure of Trading Window | View |
| 2025-12-05 | Inspection Of CompanyS Active Pharmaceutical Ingredients (Apis) Manufacturing Facility Situated At Tarapur (Palghar-Maharashtra) By US FDA | View |
| 2025-11-18 | Re-Lodgement Of Transfer Requests Of Physical Shares Report - October 2025 | View |
| 2025-11-17 | Clarification Sought On Volume Movement | View |
| 2025-11-17 | Clarification sought from Ipca Laboratories Ltd | - |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Standalone And Consolidated Q2-H1 FY26 Results And Press Release | View |
| 2025-11-13 | Board Meeting Outcome for Standalone And Consolidated Q2-H1 FY26 Results And Press Release | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-17 | Slump Sale Of Companys Apis And Drug Intermediates Manufacturing Unit Situated At Ankleshwar | View |
| 2025-10-17 | Slump Sale Of Companys Apis And Drug Intermediates Manufacturing Unit Situated At Ankleshwar | View |
| 2025-10-17 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-10-17 | Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30.09.2025 | View |
| 2025-10-16 | Incorporation Of A Wholly Owned Subsidiary In Germany | View |
| 2025-10-09 | Re-Lodgment Of Transfer Requests For Physical Shares - Sep 2025 | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-24 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |